Novartis pays $7.8 billion for Abogen mRNA asset
Novartis agreed to pay up to $7.8 billion for global rights to an early-stage mRNA therapy from China's Abogen Biosciences, the latest and largest in
GSK
Every Fin-node story mentioning GSK — 1 story, newest first.
GSK · 1 story